Hu D, Cao J, Yu H, Ding N, et al. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma. Cancer Lett 2024 May 28:216996. doi: 10.1016/j.canlet.2024.216996.
PMID: 38815797